In China, the median value of enterprise value to earnings before interest, tax, depreciation and amortization (EV/EBITDA) in the health and pharmaceuticals sector as of 2024 was a multiple of approximately 23.7x. Companies operating in the drugs (biotechnology) industry saw the highest valuation multiple with EV/EBITDA valued at 68.7x.
Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2024, by industry
Values are as of January each year. A total of 685 companies were included in the calculation for 2024.Â
Enterprise value = Market value of equity + Market value of debt - Cash. EBITDA= Estimated by adding depreciation and amortization back to operating income (EBIT). Only positive EBITDA firms.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Leonard N. Stern School of Business. (January 5, 2024). Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2024, by industry [Graph]. In Statista. Retrieved December 21, 2024, from https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/
Leonard N. Stern School of Business. "Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2024, by industry." Chart. January 5, 2024. Statista. Accessed December 21, 2024. https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/
Leonard N. Stern School of Business. (2024). Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2024, by industry. Statista. Statista Inc.. Accessed: December 21, 2024. https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/
Leonard N. Stern School of Business. "Average Ev/Ebitda Multiples in The Health and Pharmaceuticals Sector in China from 2019 to 2024, by Industry." Statista, Statista Inc., 5 Jan 2024, https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/
Leonard N. Stern School of Business, Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2024, by industry Statista, https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/ (last visited December 21, 2024)
Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2024, by industry [Graph], Leonard N. Stern School of Business, January 5, 2024. [Online]. Available: https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/
